Verastem, Inc. posts first quarter 2026 earnings, updates on RAS MAPK pathway pipeline

Verastem, Inc. posts first quarter 2026 earnings, updates on RAS MAPK pathway pipeline
Verastem posts Q1 2026 results

Verastem, Inc. released its financial results for the first quarter of 2026 and provided updates on its business operations.

The company highlighted progress with its launch activities and developments in its RAS MAPK pathway-driven pipeline programs. The announcement directs investors and stakeholders to the latest press release for additional details on financial performance and product development initiatives.

Verastem previously scheduled its first quarter earnings call for May 7 at 4:30pm ET to deliver financial results and corporate updates, according to an earlier announcement. The company also launched an LGSOC awareness campaign to highlight its FDA-approved treatment for KRAS-mutated recurrent ovarian cancer, as reported in a recent update. These activities reflect the company's ongoing engagement with both investors and patients.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.